BCMA/TNFRSF17 Antibody (1042025) [CoraFluor™ 1]

• Reactivity: Hu
• Applications: ELISA
• Clone: 1042025
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: CoraFluor 1

BCMA/TNFRSF17 Antibody (1042025) [CoraFluor™ 1] Summary

• Description: CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(TM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
  
  CoraFluor(TM) 1, amine reactive
  
  CoraFluor(TM) 1, thiol reactive
  
  For more information, please see our CoraFluor(TM) TR-FRET technology flyer.
• Immunogen: Mouse myeloma cell line NS0-derived recombinant human BCMA /TNFRSF17
  Met1-Ala54
  Accession # Q02223
• Specificity: Detects human BCMA/TNFRSF17 in direct ELISAs.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark. Do not freeze.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein A or G purified from hybridoma culture supernatant

Notes

CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254

Alternate Names for BCMA/TNFRSF17 Antibody (1042025) [CoraFluor™ 1]

• B cell maturation antigen
• B-cell maturation protein
• BCMA
• BCMAtumor necrosis factor receptor superfamily member 17
• BCMB-cell maturation factor
• CD269 antigen
• CD269
• TNFRSF13A
• TNFRSF17
• tumor necrosis factor receptor superfamily, member 17

Background

B cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a type III transmembrane glycoprotein that plays a role in B cell maturation and differentiation into plasma cells and is a therapeutic target for treatment of multiple myeloma (MM) (1,2). BMCA is synthesized as a protein of 184 amino acids (aa) in length with a theoretical molecular weight of 20.2 kDa consisting of an extracellular N-terminus containing 6 cysteine residues, a transmembrane domain, and an intracellular tumor necrosis factor (TRAF) binding domain (1). BCMA is functionally similar to two other TNFR superfamily members, B cell activation factor receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) (1,2). BCMA is primarily expressed on plasmablasts, plasma cells, and late-stage B cells (1,2).

BCMA has two agonistic ligands: BAFF and a proliferation-inducing ligand (APRIL) (1,2). APRIL has higher affinity for BCMA than BAFF and the binding is mediated by CD138/syndeclin-1 (2,3). Activation of BCMA promotes the growth and survival of plasma cells, or MM cells in disease, through several signaling pathways such as NFkappaB, MEK/ERK, AKT, JNK, and p38 (1,2). In MM cells the BCMA activation and downstream signaling cascade functions to upregulate antiapoptotic proteins including Bcl-2, Bcl-xL, and Mcl-1 and protect the cells against therapeutic agents like dexamethasone (2,3).

Given its specific expression on plasma cells but not memory B cells, naive B cells, or hematopoietic stem cells, BCMA has garnered much interest as a therapeutic target for the treatment of MM (1-4). Current BCMA-targeted immunotherapy strategies include antibody-drug conjugates (ADC), chimeric antigen receptor (CAR) T cells, bispecific T cell engager (BiTE), and bispecific/trispecific antibodies (1-4). CAR T cell therapy in particular has demonstrated promising clinical results (2,4). Still, more research needs to be done to improve the efficacy and risk of relapse following CAR T cell therapy and may also include targeting additional antigens in combination with BCMA or utilizing pharmacological agents to increase antigen density (4).

References

1. Yu, B., Jiang, T., & Liu, D. (2020). BCMA-targeted immunotherapy for multiple myeloma. Journal of hematology & oncology, 13(1), 125. https://doi.org/10.1186/s13045-020-00962-7

2. Cho, S. F., Anderson, K. C., & Tai, Y. T. (2018). Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in immunology, 9, 1821. https://doi.org/10.3389/fimmu.2018.01821

3. Dalla Palma, B., Marchica, V., Catarozzo, M. T., Giuliani, N., & Accardi, F. (2020). Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. Journal of clinical medicine, 9(9), 3022. https://doi.org/10.3390/jcm9093022

4. Mikkilineni, L., & Kochenderfer, J. N. (2021). CAR T cell therapies for patients with multiple myeloma. Nature reviews. Clinical oncology, 18(2), 71-84. https://doi.org/10.1038/s41571-020-0427-6

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.